Page 903«..1020..902903904905..910920..»

New molecular therapeutics center established at MIT’s McGovern Institute – MIT News

Posted: September 18, 2020 at 8:56 pm

More than 1 million Americans are diagnosed with a chronic brain disorder each year, yet effective treatments for most complex brain disorders are inadequate or even nonexistent.

A major new research effort at the McGovern Institute for Brain Research at MIT aims to change how we treat brain disorders by developing innovative molecular tools that precisely target dysfunctional genetic, molecular, and circuit pathways.

The K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience was established at MIT through a $28 million gift from philanthropist Lisa Yang and MIT alumnus Hock Tan 75. Yang is a former investment banker who has devoted much of her time to advocacy for individuals with disabilities and autism spectrum disorders. Tan is president and CEO of Broadcom, a global technology infrastructure company.This latest gift brings Yang and Tans total philanthropy to MIT to more than $72 million.

In the best MIT spirit, Lisa and Hock have always focused their generosity on insights that lead to real impact," says MIT President L. Rafael Reif. Scientifically, we stand at a moment when the tools and insights to make progress against major brain disorders are finally within reach. By accelerating the development of promising treatments, the new center opens the door to a hopeful new future for all those who suffer from these disorders and those who love them. I am deeply grateful to Lisa and Hock for making MIT the home of this pivotal research.

Engineering with precision

Research at the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience will initially focus on three major lines of investigation: genetic engineering using CRISPR tools, delivery of genetic and molecular cargo across the blood-brain barrier, and the translation of basic research into the clinical setting. The center will serve as a hub for researchers with backgrounds ranging from biological engineering and genetics to computer science and medicine.

Developing the next generation of molecular therapeutics demands collaboration among researchers with diverse backgrounds, says Robert Desimone, McGovern Institute director and the Doris and Don Berkey Professor of Neuroscience at MIT. I am confident that the multidisciplinary expertise convened by this center will revolutionize how we improve our health and fight disease in the coming decade. Although our initial focus will be on the brain and its relationship to the body, many of the new therapies could have other health applications.

There are an estimated 19,000 to 22,000 genes in the human genome and a third of those genes are active in the brain the highest proportion of genes expressed in any part of the body. Variations in genetic code have been linked to many complex brain disorders, including depression and Parkinsons disease. Emerging genetic technologies, such as the CRISPR gene editing platform pioneered by McGovern Investigator Feng Zhang, hold great potential in both targeting and fixing these errant genes. But the safe and effective delivery of this genetic cargo to the brain remains a challenge.

Researchers within the new Yang-Tan Center will improve and fine-tune CRISPR gene therapies and develop innovative ways of delivering gene therapy cargo into the brain and other organs. In addition, the center will leverage newly developed single-cell analysis technologies that are revealing cellular targets for modulating brain functions with unprecedented precision, opening the door for noninvasive neuromodulation as well as the development of medicines. The center will also focus on developing novel engineering approaches to delivering small molecules and proteins from the bloodstream into the brain. Desimone will direct the center and some of the initial research initiatives will be led by associate professor of materials science and engineering Polina Anikeeva; Ed Boyden, the Y. Eva Tan Professor in Neurotechnology at MIT; Guoping Feng, the James W. (1963) and Patricia T. Poitras Professor of Brain and Cognitive Sciences at MIT; and Feng Zhang, James and Patricia Poitras Professor of Neuroscience at MIT.

Building a research hub

My goal in creating this center is to cement the Cambridge and Boston region as the global epicenter of next-generation therapeutics research. The novel ideas I have seen undertaken at MITs McGovern Institute and Broad Institute of MIT and Harvard leave no doubt in my mind that major therapeutic breakthroughs for mental illness, neurodegenerative disease, autism, and epilepsy are just around the corner, says Yang.

Center funding will also be earmarked to create the Y. Eva Tan Fellows program, named for Tan and Yangs daughter Eva, which will support fellowships for young neuroscientists and engineers eager to design revolutionary treatments for human diseases.

We want to build a strong pipeline for tomorrows scientists and neuroengineers, explains Hock Tan. We depend on the next generation of bright young minds to help improve the lives of people suffering from chronic illnesses, and I can think of no better place to provide the very best education and training than MIT.

The molecular therapeutics center is the second research center established by Yang and Tan at MIT. In 2017, they launched the Hock E. Tan and K. Lisa Yang Center for Autism Research, and, two years later, they created a sister center at Harvard Medical School, with the unique strengths of each institution converging toward a shared goal: understanding the basic biology of autism and how genetic and environmental influences converge to give rise to the condition, then translating those insights into novel treatment approaches.

All tools developed at the molecular therapeutics center will be shared globally with academic and clinical researchers with the goal of bringing one or more novel molecular tools to human clinical trials by 2025.

We are hopeful that our centers, located in the heart of the Cambridge-Boston biotech ecosystem, will spur further innovation and fuel critical new insights to our understanding of health and disease, says Yang.

Read more:
New molecular therapeutics center established at MIT's McGovern Institute - MIT News

Posted in Molecular Medicine | Comments Off on New molecular therapeutics center established at MIT’s McGovern Institute – MIT News

Scientists outraged by White House appointees’ meddling with coronavirus information: ‘Outright egregious’ – USA TODAY

Posted: September 18, 2020 at 8:56 pm

Without masks and a vaccine, we could reach Herd Immunity from COVID-19, but deaths would skyrocket. We break down the science of it. USA TODAY

Scientists and physicians reacted with words such as aghast, despicable and outrageous over the weekend as news spread that White House appointeesinterfered with a basic national public health reportwhen it conflicted with PresidentDonald Trump'scoronavirus messaging.

Michael Caputo, the Health and Human Services assistant secretary for public affairs, acknowledged Saturday that since June, he and an adviser havescrutinized and at times pushed for changes toa weekly health report distributed by the U.S. Centers for Disease Control and Prevention.

The meddling, first reported by Politico,included efforts to stop the publication of a report last week on the use of hydroxychloroquine,a malaria drug often touted by Trump, delaya10-state study of COVID-19 infection statistics in Juneand another on the spread of coronavirus at a Georgia sleep-away camp.

The Morbidity and Mortality Weekly Report is a series of dry and sometimes dense briefupdates on public health incidents that comeout on Thursdays. They typically describeevents or topicsand are an important way for doctors and health officials to get the latest data.

Monday, members of the House Select Subcommittee on the Coronavirus Crisis sent a letter to HHS Secretary AlexAzar and CDC Director Robert Redfield requesting documents pertaining to the efforts to block the publicationof "accurate scientific reports."

"We are gravely concerned by reports showing that the Presidents political appointees at HHS have sought to help him downplay the risks of the coronavirus crisis by attempting to alter, delay, and block critical scientific reports from CDC," the letter said.

Approving a vaccine in the U.S. usually takes years, but COVID-19 vaccines are moving through in record time. What does that mean? USA TODAY

The sprint to create a COVID-19 vaccine started in January. The finish line awaits.

Dr. William Schaffner, who is on the publications editorial board, said he was aghast and appalled" by the reported attempts to delay, stop or change reports.He described the publication as a vital part of the global conversation among public health officials who track diseases and dangers.

It has been the voice of the U.S. governments health system, of integrity and scientific rigor, for years," said Schaffner, a professor and infectious disease expert at the Vanderbilt University School of Medicine in Nashville, Tennessee."Indeed, the MMWR has been a model for other countries ministries of public health for creating similar newsletters in their countries.

The interference is not just anti-science butdisinformation intended to deceive the American public, said Dr. Eric Topol, a professor of molecular medicine at the Scripps Research Institute in La Jolla, California.

This is outright egregious. Its despicable, Topol said, accusing Redfieldand otherleadersof allowing the agency to be hijacked by politics.

Coronavirus in America: Here's how the virus is spreading, state by state

What were seeing is multiple actors, important people who are just laying down, who are complicit with the anti-science machinations of the Trump administration, he said.

In an interview Saturday with The Washington Post,Caputo alleged the content of the MMRWis being politicized by the agency itself.

But in an election year, and in the time of COVID-19,its no longer unanimously scientific. Theres political content, The Post quoted Caputo as saying.

On a Facebook livestream on Sunday night, Caputo railed against what he termed"sedition" among CDC scientists, the New York Times reported Monday.They havent gotten out of their sweatpants except for meetings at coffee shops to plot how theyre going to attack Donald Trump next, the Times reported him as saying. The Facebook video has since been removed.

On Twitter,Dr. Sherri Bucher, a global health researcher, wrote,There are no words to articulate how horrific this is. Trust & credibility, shattered, overnight. MMWR has been, for a long time, one of the most reliable, steadfast, scientific resources; unquestioned veracity, impeccable reputation for quality of data/analysis. No longer.

It is not unusual for communicationpeople within the CDC to be involved in an MMWR report before publication, said Dr. Patrick Remington, a member of the journals editorial board and a former CDC staffer.

That involvement was previously restricted to officials within the agency who let political leaders know what was coming so they could be prepared with a communicationstrategy, said Remington, associate dean for public health at the School of Medicine and Public Health at theUniversity of Wisconsin-Madison.

What is unusual is the allegation that the political process is attempting to influence the scientific conclusions. And thats a concern, Remington said.

A member of the editorial board for 14 years, Remington said the body meets roughly once a year to help decide the publication's big-picture vision. Its most recent meeting was in February.

Coronavirus Watch: An American dies of COVID-19 every 2 minutes

The board is not involved in the publication's day-to-day operations, and members knew nothing about the accusations of interferenceuntil they read about them, he and others said.

Jeff Niederdeppe, another member of the MMWR editorial board and a professor of public health communicationat Cornell University, said political meddling could erode public faith and cause long-term damage to the publication.

The big issue here in my mind is the fundamental undermining of trust, he said, both in the CDC generallyand among the public health practitioners who rely on the MMWR to make policy decisions. If that very foundation is being politicized, its incredibly alarming.

Regaining trust is a challenge, he said, and should begin with an immediate response from the CDC, which has not commented on the allegations.

If the concerns are confirmed, Niederdeppe said, Id be interested in convening with the other members of the MMWR editorial board to figure out what we could do in this role.

The Notes from the Field section of the MMWR previews small investigations by state or local health departments that illustrate a specific problem.

Theyre like an alert mechanism, Schaffner said.

MMWRs have described American heat-related deaths by sex and age, top foods contributing to high-salt intake, an outbreak of tuberculosis among workers at food processing plants and drinking rates among pregnant women.

Dr. Jennifer Kates, senior vice president of the nonprofit Henry J. Kaiser Family Foundation, which focuseson health issues, described the MMWR as the go-to public health publication.

The MMWR predates the CDC, beginning as a publication of the U.S. Public Health Servicein 1878.

Kates said she was disturbed by what appears to be the insertion of politics into a well-respected scientific journal. In general, the politicization of COVID has been the enemy of public health, she said.

MMWR reports are written by CDC staff, as well as public health workers and physicians nationwide. The one- to two-page reports are known for their meticulous and careful editing, a process those who'vegone through it described as harrowing.

If youve ever been involved as a co-author of one of those reports, its painful how carefully every sentence is reviewed for scientific rigor, for precision,Schaffner said.

The Centers for Disease Control and Prevention issues the Morbidity and Mortality Weekly Report every Thursday.(Photo: Jessica McGowan, Getty Images)

Read or Share this story: https://www.usatoday.com/story/news/health/2020/09/13/covid-scientists-white-house-meddling-cdc-mmwr/5787230002/

See the rest here:
Scientists outraged by White House appointees' meddling with coronavirus information: 'Outright egregious' - USA TODAY

Posted in Molecular Medicine | Comments Off on Scientists outraged by White House appointees’ meddling with coronavirus information: ‘Outright egregious’ – USA TODAY

HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean? – The DBT News

Posted: September 18, 2020 at 8:56 pm

HTG Molecular Diagnostics Inc. [NASDAQ: HTGM] surged by $0.0 during the normal trading session on Thursday and reaching a high of $0.35 during the day while it closed the day at $0.34. The company report on September 8, 2020 that HTG Molecular Diagnostics to Present Corporate Overview at Fall Investor Conferences.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced John Lubniewski, President and CEO of HTG, will present virtually at the H.C. Wainwright 22nd Annual Global Investment Conference and at the Cantor Fitzgerald Global Healthcare Conference. Details are as follows:.

About HTG.

HTG Molecular Diagnostics Inc. stock has also gained 6.01% of its value over the past 7 days. However, HTGM stock has declined by -52.85% in the 3 months of the year. Over the past six months meanwhile, it has lost -1.16% and lost -51.28% year-on date.

The market cap for HTGM stock reached $25.48 million, with 65.76 million shares outstanding and 49.64 million shares in the current float. Compared to the average trading volume of 4.77M shares, HTGM reached a trading volume of 2065978 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Cantor Fitzgerald have made an estimate for HTG Molecular Diagnostics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 11, 2020. The new note on the price target was released on March 26, 2020, representing the official price target for HTG Molecular Diagnostics Inc. stock. Previously, the target price had yet another raise from $4.50 to $6, while Rodman & Renshaw kept a Buy rating on HTGM stock.

The Average True Range (ATR) for HTG Molecular Diagnostics Inc. is set at 0.04, with the Price to Sales ratio for HTGM stock in the period of the last 12 months amounting to 1.77. The Price to Book ratio for the last quarter was 1.22, with the Price to Cash per share for the same quarter was set at 0.44.

HTG Molecular Diagnostics Inc. [HTGM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.01. With this latest performance, HTGM shares dropped by -27.00% in over the last four-week period, additionally sinking by -1.16% over the last 6 months not to mention a drop of -56.99% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTGM stock in for the last two-week period is set at 37.10, with the RSI for the last a single of trading hit 41.28, and the three-weeks RSI is set at 37.50 for HTG Molecular Diagnostics Inc. [HTGM]. The present Moving Average for the last 50 days of trading for this stock 0.5115, while it was recorded at 0.3292 for the last single week of trading, and 0.5346 for the last 200 days.

Operating Margin for any stock indicates how profitable investing would be, and HTG Molecular Diagnostics Inc. [HTGM] shares currently have an operating margin of -102.09 and a Gross Margin at +53.60. HTG Molecular Diagnostics Inc.s Net Margin is presently recorded at -100.49.

Return on Total Capital for HTGM is now -49.79, given the latest momentum, and Return on Invested Capital for the company is -53.22. Return on Equity for this stock declined to -85.65, with Return on Assets sitting at -43.42. When it comes to the capital structure of this company, HTG Molecular Diagnostics Inc. [HTGM] has a Total Debt to Total Equity ratio set at 71.00. Additionally, HTGM Total Debt to Total Capital is recorded at 41.52, with Total Debt to Total Assets ending up at 37.72. Long-Term Debt to Equity for the company is recorded at 50.39, with the Long-Term Debt to Total Capital now at 29.47.

Reflecting on the efficiency of the workforce at the company, HTG Molecular Diagnostics Inc. [HTGM] managed to generate an average of -$172,301 per employee. Receivables Turnover for the company is 4.70 with a Total Asset Turnover recorded at a value of 0.43.HTG Molecular Diagnostics Inc.s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.10 and a Current Ratio set at 7.40.

With the latest financial reports released by the company, HTG Molecular Diagnostics Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.16/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HTGM.

There are presently around $6 million, or 34.30% of HTGM stock, in the hands of institutional investors. The top three institutional holders of HTGM stocks are: NANTAHALA CAPITAL MANAGEMENT, LLC with ownership of 5,060,160, which is approximately 0% of the companys market cap and around 0.80% of the total institutional ownership; COWEN PRIME SERVICES LLC, holding 4,579,500 shares of the stock with an approximate value of $1.57 million in HTGM stocks shares; and PERKINS CAPITAL MANAGEMENT INC, currently with $0.83 million in HTGM stock with ownership of nearly -3.68% of the companys market capitalization.

Positions in HTG Molecular Diagnostics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 17 institutional holders increased their position in HTG Molecular Diagnostics Inc. [NASDAQ:HTGM] by around 1,592,904 shares. Additionally, 17 investors decreased positions by around 3,162,056 shares, while 8 investors held positions by with 11,662,409 shares. The mentioned changes placed institutional holdings at 16,417,369 shares, according to the latest SEC report filing. HTGM stock had 7 new institutional investments in for a total of 1,062,389 shares, while 11 institutional investors sold positions of 2,750,997 shares during the same period.

More:
HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean? - The DBT News

Posted in Molecular Medicine | Comments Off on HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean? – The DBT News

Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision…

Posted: September 18, 2020 at 8:56 pm

Dublin, Sept. 18, 2020 (GLOBE NEWSWIRE) -- The "National eHealth Initiatives Advancing Global Precision Medicine Market, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

This research service analyzes the key building blocks for the precision medicine ecosystem to provide strategic imperatives and growth opportunities for key participants.

Key Issues Addressed

The study captures both the global and regional flavors for PM market opportunity realization such as: market projections, drivers and restraints, country readiness index, and major government and commercial initiatives. The study also provides live case studies and innovative business models for leading companies in the PM space.

Precision medicine is transitioning toward wider acceptance, due to mounting payer pressures and regulatory changes that are shifting pharma businesses from prescriptive to more predictive and personalized models. Emergence of value-based reimbursement models and healthcare consumerism trends are helping move the treatment model from one-size-fits-all' to a stratified and outcome-based targeted therapeutics concept called precision medicine' (PM).

Companion diagnostics (CDx) and targeted therapeutics (TRx) are going beyond oncology and spreading more toward therapeutic areas such as infectious diseases, central nervous system (CNS), and cardiovascular diseases. Despite a relatively high success rate for PM R&D assets commercialization in recent years, considerable challenges exist around proving clinical utility and a regulatory and reimbursement framework, which is rigid, decentralized, and non-uniform.

Advances in omics technologies help in identifying molecular targets with the help of molecular insights generated by datasets about the disease pathogenesis. PM informatics is the key component of the PM ecosystem. PM-cognitive analytic platforms capable of leveraging genomic, clinical, financial, and lifestyle data, while delivering actionable clinical insights at the point of care, are gaining market traction. Big Data and Artificial Intelligence (AI) are the key enablers for utilizing the full potential of PM for building predictive models based on multi-omics data, given a big hurdle in the adoption of PM is lack of technology infrastructure.

Genomic sequencing has huge potential to support the COVID-19 outbreak exploration, especially in comprehending the re-emergence of potential COVID-19 outbreaks.

In terms of geographic outlook, although the specific focus on PM research started in the United States and the EU, countries such as Canada, China, Australia, Taiwan, South Korea, Singapore, and Japan have made significant advances in recent years in this area by way of significant investments to develop in-country research and scientific expertise to improve access. Considering the infrastructure requirements for utilizing omics in clinical practice, China and Japan are beating other leading countries in terms of both research initiatives and regulations and infrastructure development.

Key Topics:

Executive SummaryKey Questions This Study Will Answer6 Big Themes for Precision MedicinePrecision Medicine - Regional Market OverviewPrecision Medicine Vendor Landscape by Major Market ClustersPrecision Medicine Readiness of Major CountriesKey InsightsPrecision Medicine in the Wake of COVID-19

Research Scope, Definitions, and SegmentationResearch ScopePersonalized Vs Precision MedicinePrecision Medicine CategoriesPatient Stratification - Data Volume, Sources, and AdoptionPrecision Medicine - Key Segments and Data Sources

Current and Future State of Precision MedicineGlobal Precision Medicine Market - Macro to Micro VisioningChanging Modalities of Innovative DrugsPrecision Medicine in the Late-stage Clinical Trials PipelineMajor Pharmacogenomics BiomarkersPrecision Medicine Vendor Landscape

Precision Medicine Market Projections (2019–2025)Scenario Contingent Projections for Core Precision Medicine SegmentForecast Assumptions for Core Precision Medicine Segment - Optimistic ScenarioForecast Assumptions for Core Precision Medicine Segment - Pessimistic ScenarioCore Precision Medicine Segment - Revenue Forecast Scenario AnalysisCore Precision Medicine Segment - Revenue Forecast by SubsegmentsForecast Assumptions - Core Precision Medicine Key Subsegments

Precision Medicine Cluster Benchmarking by Major CountriesSelect Countries’ Readiness for Precision MedicineFactors Consideration for Precision Medicine Country Readiness IndexCountry Readiness for Precision Medicine - USCountry Readiness for Precision Medicine - EU and UKCountry Readiness for Precision Medicine - APAC

Growth Opportunities in Precision MedicineMajor Growth Opportunities

Opportunity Analysis - CDx and Biomarker-based Targeted Therapeutics (TRx)Growth Opportunity 1 - CDx and Biomarkers-based TRxPrecision Medicine Clinical Trials Trends in Major RegionsTop Areas of Companion Biomarker ResearchNew Clinical Trial Designs in the Era of Precision MedicineSelect Countries’ TRx and CDx Readiness Index

Opportunity Analysis - Genomics Technologies for Precision DiagnosticsGrowth Opportunity 2 - Genomics Technologies for Precision DiagnosticsPrecision Medicine Patient Stratification by Omics/Diagnostic FactorsLevel of Adoption of Select Novel Technologies and ApproachesGenomics Technologies for Precision DiagnosticsSelect NGS Vendor LandscapeSelect Countries’ Omics Research Readiness Index

Opportunity Analysis - Precision Medicine InformaticsGrowth Opportunity 3 - Precision Medicine Informatics SolutionsPrecision Medicine Informatics Market LandscapePrecision Medicine Informatics Market SizeC2A: Xifin - Precision Medicine Informatics for MDxSelect Countries’ eHealth Readiness Index

Key Conclusions

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/lvkzh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Go here to see the original:
Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision...

Posted in Molecular Medicine | Comments Off on Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision…

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune…

Posted: September 18, 2020 at 8:56 pm

DetailsCategory: Proteins and PeptidesPublished on Friday, 18 September 2020 10:55Hits: 201

- Series A led by Canaan Partners, Samsara BioCapital and The Column Group- Foundational research into cytokine structural biology and immune function licensed from Stanford University- Nils Lonberg joins founding investors on board of directors

MENLO PARK, CA, USA I September 17, 2020 I Synthekine Inc., an engineered cytokine therapeutics company, today announced the closing of an $82 million Series A financing. The financing was co-led by Canaan Partners, Samsara BioCapital and The Column Group, with participation from other undisclosed investors. Synthekine was founded by K. Christopher Garcia, Ph.D., to leverage discoveries showing that cytokines can be tuned to enhance their therapeutic effects.

Synthekine combines strengths in immunology, structural insights on cytokines and multiple engineering technologies to create optimized therapeutics against new and validated cytokine targets for the treatment of cancer and autoimmune disorders. Proceeds from this Series A financing will be used to advance Synthekines lead therapeutic programs into clinical studies, expand its discovery pipeline and hone its proprietary cytokine engineering platforms. The company currently has two lead programs in IND-enabling development: STK-012, an engineered Interleukin-2 (IL-2) partial agonist for the treatment of cancer, and the combination of STK-009 and SYNCAR-001, an orthogonal IL-2 ligand and a CD-19 CAR-T-cell therapy being studied in combination.

Cytokines have a fundamental role in the immune system and represent an enormous opportunity for innovative therapeutics. However, most cytokines broadly activate a wide range of cells that can simultaneously stimulate and suppress the immune system, making drug development against these targets challenging, said Debanjan Ray, chief executive officer of Synthekine. Chris Garcia has shown, for a wide range of therapeutically important cytokines, that cytokine efficacy and toxicity can be decoupled through structure-based protein engineering. These findings mean that many cytokines previously thought to be unsuitable as therapeutics can be transformed into safe and effective drugs. In addition to our highly differentiated IL-2-based programs, we have assembled multiple best-in-class technologies and an accomplished team to develop cytokine therapeutics by engineering them at the molecular level to enhance their activity and selectivity.

Unlocking cytokine therapeutics through unique structural biology insights

Cytokines are small, soluble proteins that are powerful regulators of the immune system and can stimulate a wide range of immune cells, primarily driven by their binding and interaction with cell surface receptors. Most cytokines are pleiotropic, meaning that a given cytokine can exert a range of responses across multiple cell types. Pleiotropy has proven to be a significant obstacle in the development of cytokine therapeutics. Existing cytokine therapeutics, such as aldesleukin (Proleukin) and interferons, demonstrate meaningful efficacy in cancer and other diseases but are limited by significant side effects.

Synthekine has licensed several cytokine programs and platforms from Stanford University. Research conducted in the Garcia lab at Stanford led to insights into the interaction of cytokines and their receptors, allowing researchers to engineer modified cytokines to deliver selective activity to particular cell types of therapeutic interest, giving them the potential for optimized efficacy, a larger therapeutic window and improved safety for patients. This research has been responsible for determining the three-dimensional structures for many different cytokine/receptor complexes, including IL-1, IL-2, IL-4, IL-6, IL-13, IL-15, IL-17, IL-23 and the three different classes of interferons.

A deep preclinical pipeline and proprietary platform

Synthekine is advancing several preclinical programs and innovative platform technologies. These include:

A collaborative company formation effort and seasoned leadership team

The founding members of Synthekines board of directors include Tim Kutzkey, Ph.D., managing partner of The Column Group; Srinivas Akkaraju, Ph.D., founding partner of Samsara BioCapital; and Julie Grant, general partner at Canaan Partners. Synthekine has also appointed biopharma veteran Nils Lonberg as an independent member of its board of directors.

Synthekines executive team is led by Debanjan Ray as chief executive officer. Mr. Ray was previously chief financial officer and head of business development at CytomX Therapeutics, where he was responsible for leading financing efforts and securing multiple strategic collaborations with major pharmaceutical companies that generated more than $400 million in upfront payments and up to $4 billion in milestones. The executive team also includes Martin Oft, M.D., as chief development officer, Rob Kastelein, Ph.D., as head of therapeutic discovery and Gregory Yedinak as senior vice president of technical operations.

Synthekines scientific advisory board is led by its founder, K. Christopher Garcia, Ph.D., professor of molecular and cellular physiology and structural biology at Stanford University School of Medicine, a Howard Hughes Medical Institute (HHMI) investigator and a member of both the National Academy of Sciences and the National Academy of Medicine.

About Synthekine

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system. For more information, visit http://www.synthekine.com.

SOURCE: Synthekine

View original post here:
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune...

Posted in Molecular Medicine | Comments Off on Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune…

2bPrecise Wins Industry Innovation Award – Bio-IT World

Posted: September 18, 2020 at 8:56 pm

Fierce Healthcare honors the precision medicine platform for clinical information management capabilities

RALEIGH, NC, UNITED STATES - Sep 16, 2020 - Fierce Healthcare released its annual Fierce Innovation Report this week, naming 2bPrecise the industrys top clinical information management solution. The intent of the awards program, according to Fierce Healthcare, is to showcase organizations that over the past 12 months have demonstrated innovative solutions that have the greatest potential to save money, engage patients, or revolutionize the industry.

Cloud-based, the 2bPrecise platform consumes molecular data from labs and clinical information from the EHR, synthesizing them into a clinical-genomic ontology. The resulting precision medicine insights are delivered to providers within their familiar workflow across any EHR. Plus, the solution is built to interact with evolving knowledge sources and care guidelines.

These unique capabilities enable health systems to leverage precision medicine insights in myriad ways - driving efficient workflows for genomics interventions, extracting population analytics, building cohorts for trial recruitment, enabling participation in research studies and more.

2bPrecise was similarly honored with the MedTech Breakthrough award as Best Overall Genomics Solution earlier this year, and the company received Microsoft Corp.s 2020 Health Innovation Award in the category of Reimagine Healthcare. Industry Wired magazine further recognized 2bPrecise as one of the Top 8 Precision Medicine Companies in the USA this year.

We are honored to receive this latest recognition from Fierce Healthcare, said 2bPrecise CEO Assaf Halevy. The entire 2bPrecise team is driven to create excellent solutions to support clinical decision making within the providers workflow - while simultaneously helping improve outcomes and the patient experience.

Additional winners announced by Fierce Healthcare include Roche (data analytics/business intelligence), Walgreens (digital/mobile health solutions), XSOLIS (financial/operational) and Centivo (population health management/patient engagement).

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM) brings the resulting precision medicine insights into a physicians EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at http://www.2bPreciseHealth.com.

Media Contact

Erica Navar

Account Executive

Aria Marketing (for 2bPrecise)

(909) 538-9541

enavar@ariamarketing.com

Originally posted here:
2bPrecise Wins Industry Innovation Award - Bio-IT World

Posted in Molecular Medicine | Comments Off on 2bPrecise Wins Industry Innovation Award – Bio-IT World

Stem cells, like Rosh Hashanah, give the opportunity to be reborn – The Jerusalem Post

Posted: September 16, 2020 at 1:59 pm

Rosh Hashanah is the day of pregnancy of the world. Hayom Harat Olam (The day of creation of the world). What does it mean?Medical research today is focusing on a fascinating and visionary field, which is the study of "stem cells."The uniqueness of stem cells comes from two main features which distinguish them from other cells. The first is that they are still 'neutral cells', meaning, they have not yet received their final identity and purpose in the body, so they have not yet finalized their differentiation process. As a result of this, they are able to differentiate and can develop into one of many types of mature cells, such as a skin cell, a muscle cell or a blood cell. By doing so, new cells are created, which can regenerate various tissues and organs.The second unique feature of stem cells is that they are able to divide and multiply infinitely and produce identical cells. Thus, a constant pool of unsorted stem cells that have not acquired a final designation is preserved.The possibilities of healing, cell regeneration and the human body in general are fascinating, and the field of stem cells is one of the leading fields in the world. Its healing potentials are so vast, not only when it comes to repairing the damaged, but also recreating something more true and precise.When I think of Rosh Hashanah from a spiritual standpoint, it feels like today is the birth of the world. We have before us 353 days (because some Jewish months arent full) which have not yet been defined by how they will play out and how they will look. It is unknown how we will succeed as individuals, and how we will succeed as nation. Interestingly, the second feature that exists with stem cells also connects to Rosh Hashanah. On this holy day, we are praying and asking Hashem from a place of "anything is possible" there are no boundaries, no glass barriers, no one is stopping us from simply praying and asking. cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });Hashem, everything is completely in our hands! We can change the world and create something entirely new. Rosh Hashanah gives us the opportunity to create and build anew; its the source of rebirth for the relationship between man and his friend, man and Hashem, and of course, man as one who is part of a nation and of the entire world.It's not for nothing that it is written in the Talmud Yerushalmi that whoever spends his time on Rosh Hashanah sleeping, his luck will also sleep. It's the time to act, ask, beg and change.The cells will divide, the decisions made will be in place, and the abundance from shamayim (heaven) will come down. We now have a very great ability and opportunity to influence that. Please dont miss out on this opportunity!Be that as it may, today is Harat Olam the pregnancy of the world. It is our responsibility to pray that this pregnancy will be the best it can be. Have a happy and sweet New Year.Rabbi Yitzak Neriya is the head of the Torah Betzion yeshiva and founder of the Echad Lechad (One to One) foundation.

See original here:
Stem cells, like Rosh Hashanah, give the opportunity to be reborn - The Jerusalem Post

Posted in Stem Cells | Comments Off on Stem cells, like Rosh Hashanah, give the opportunity to be reborn – The Jerusalem Post

Global Hematopoietic Stem Cells Transplantation Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 – The Daily…

Posted: September 16, 2020 at 1:59 pm

A comprehensive research study titled Global Hematopoietic Stem Cells Transplantation Market 2020 by Company, Regions, Type and Application, Forecast to 2025 presents a basic overview of the industry including definitions, classifications, applications, and chain structure. The report sheds light on the current market scenario that demonstrates value chain structure, market size, regional analysis, application, and forecast. The report contains a thorough analysis of global Hematopoietic Stem Cells Transplantation market drivers, restraints, threats, and opportunities as well as the lucrative investment options for the players in the coming years to 2025. It studies the historical and forecasted number of companies and breaks them down by company size. The report includes data about opportunities that will completely change the business environment in the coming years.

The report highlights driving factors, restraining factors, and industry news like mergers, acquisitions, and investments. Vital points such as price, cost, and gross revenue are analyzed for types, companies, and regions. With this data, the sale price for various types, applications, and regions is also included in the global Hematopoietic Stem Cells Transplantation market. For each player, product details, capacity, price, cost, gross and revenue numbers are given. Their contact information is provided for better understanding. It further examines competitive developments such as mergers and acquisitions, agreements, collaborations, and partnerships.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/99747

Key Figures:

There are various factors considered for assessing the players studied in the global Hematopoietic Stem Cells Transplantation market report: production sites, price, gross margin, revenue, production, product application, product specification, and product introduction. Readers are provided with detailed manufacturing process analysis, industrial chain analysis, manufacturing cost structure analysis, and raw materials analysis. Under raw materials analysis, the report includes details about key suppliers of raw materials, the price trend of raw materials, and important raw materials. The analysts explore critical influence factors, market drivers, challenges, risk factors, opportunities, and market trends. The readers are informed about their gross margin, price, revenue, and production growth rate here.

The study encompasses profiles of top major companies/manufacturers operating in the global Hematopoietic Stem Cells Transplantation market. Key players profiled in the report include: CBR Systems, Lonza Group, Thermo Fisher Scientific, China Cord Blood Corporation, Merck Millipore, ViaCord, ThermoGenesis, Vcanbio, STEMCELL Technologies, CellGenix Technologie Transfer

In market segmentation by type, the report covers: Stem Cells Storage, Stem Cells Consumables

In market segmentation by applications, the report covers the following uses: Leukemia, Lymphoproliferative Disorders, Solid Tumors, Non-Malignant Disorders

The report provides a forecast (2020-2025) assessed based on how the market is predicted to grow in major regions like: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/99747/global-hematopoietic-stem-cells-transplantation-market-2020-by-company-regions-type-and-application-forecast-to-2025

Some of The Key Topics Covered In The Report Include:

The report covers significant statistics related to the global Hematopoietic Stem Cells Transplantation industry along with products, size, price analysis, demand & supply, and production and consumption rate. After the basic analysis, the report studies the production, production plants, their capacities, global production, and revenue. The overall report is presented in an efficient way that involves basic outline, agreements, and certain facts as per comprehension.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Other Related Reports Here :

Global Medication Adherence Packaging Systems Market 2020 Key Performance, Top Players, Segmentation, Future Plans and Forecast to 2025

Global Ammonium Sulfate Market 2020 Key Players Analysis, Segmentation, Industry Size, Growth, Trend and Forecast by 2025

Global Talc Market 2020 Key Drivers and Challenges, Opportunities and Forecast Insights by 2025

Global Bio-decontamination Equipment Market 2020 Top Industry Trend and Segments Analysis upto 2025

Global Biodegradable Mulch Film Market 2020 Introduction, Definition, Specifications, Classification and Industry Scope by 2025

Global Acetyl Tributyl Citrate (ATBC) Market 2020 Industry Overview, Competition by Manufacturers, Production Capacity by Region, Forecast by 2025

Excerpt from:
Global Hematopoietic Stem Cells Transplantation Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 - The Daily...

Posted in Stem Cells | Comments Off on Global Hematopoietic Stem Cells Transplantation Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 – The Daily…

Sanford Health launches first-of-its-kind study of umbilical stem cells as COVID-19 treatment – The Daily Republic

Posted: September 16, 2020 at 1:59 pm

SIOUX FALLS, S.D. Sanford Health is launching a first-of-its-kind study that uses umbilical stem cells to treat people sick with COVID-19.

The Sioux Falls-based health system has enrolled five patients at Sanford USD Medical Center in Sioux Falls in the trial, which uses umbilical cord lining stem cells to treat patients with moderate to severe COVID-19 both before and every they've been placed on a ventilator, it announced Tuesday, Sept. 8. It may expand the study to patients in Fargo.

We are optimistic about the potential improvement with this treatment, Dr. W. Chad Spanos, principal investigator of the clinical trial at Sanford Health, said in a news release. We look forward to enrolling more patients onto this trial and bringing promising new treatment options to our patients bedside in the future.

The randomized, placebo-controlled and blinded phase 1/2a study will look at whether infusing patients with the stem cells could be a safe and effective treatment for COVID-19. The trial also aims to identify the population that will benefit most optimally by enrolling patients with moderate to severe COVID-19.

Sanford Health is the largest rural nonprofit health care system in the nation with clinics across the Upper Midwest and major medical centers in Sioux Falls, Fargo and Bemidji, Minn.

Were committed to bringing the best treatments and discoveries to our patients first, David A. Pearce, president of innovation and research at Sanford Health, said in a news release. We are thrilled to be the first health system in the country to open this trial and offer access to a novel treatment option to our patients with severe cases of COVID-19.

The study will use cells provided by RESTEM, a biotechnology firm which uses a proprietary process to rapidly replicate millions of doses from umbilical cord tissue.

Its a pleasure to work with Sanford Health and their team of professionals, said Dr. Rafael Gonzalez, senior vice president of research & development for RESTEM. We have spent many years researching the properties of (umbilical cord lining stem cells) in order to assure we are delivering the best quality cells that may provide a robust response. We look forward to the results of the study.

Read this article:
Sanford Health launches first-of-its-kind study of umbilical stem cells as COVID-19 treatment - The Daily Republic

Posted in Stem Cells | Comments Off on Sanford Health launches first-of-its-kind study of umbilical stem cells as COVID-19 treatment – The Daily Republic

STEM CELL UMBILICAL CORD BLOOD MARKET TRENDS, GROWTH, REGIONAL ANALYSIS, GROWTH REVENUE WITH TOP COMPANY’S AND FORECAST TO 2027 The Daily Chronicle -…

Posted: September 16, 2020 at 1:59 pm

Stem Cell Umbilical Cord Blood research report provides deep insights into the Global Stem Cell Umbilical Cord Blood market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Stem Cell Umbilical Cord Blood during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Biotechnology Industry, and many more. Trade barriers are further restraining the demand- supply outlook. As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Stem Cell Umbilical Cord Blood market globally. This report on Stem Cell Umbilical Cord Blood market provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

Get Sample PDF athttps://www.theinsightpartners.com/sample/TIPRE00005170/

Stem cells from umbilical cord blood is preserved as it has capabilities of regenerating into any type of body cells. In life threatening malignant and non-malignant diseases, hematopoietic stem cells transplantation (HSCT) can help in saving the life of person. In addition, the therapy is comparatively cost effective and has limited side effects. Umbilical stem cells are used for treating cancer, blood diseases like anemia and certain immune system disorders.

The stem cell umbilical cord blood (UCB) market is anticipated to grow in the forecast period owing to increasing occurrence of chronic diseases as well as rising support of government and private sector for research and development. In addition, the growing popularity for umbilical cord storage in developing countries is expected to create opportunities for market growth during the forecast period

Key players:

Detailed segmentation of the market, on the basis of Storagr Option, Disease, End User, Geography and a descriptive structure of trends of the segments and sub-segments are elaborated in the report. It also provides the market size and estimates a forecast from the year 2018 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The report also provides exhaustive PEST analysis for all five regions after evaluating political, economic, social and technological factors effecting the Stem Cell Umbilical Cord Blood market.

Key Reasons:

Buy Complete Report athttps://www.theinsightpartners.com/buy/TIPRE00005170/

About us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact us: Call: +1-646-491-9876Email:[emailprotected]

Visit link:
STEM CELL UMBILICAL CORD BLOOD MARKET TRENDS, GROWTH, REGIONAL ANALYSIS, GROWTH REVENUE WITH TOP COMPANY'S AND FORECAST TO 2027 The Daily Chronicle -...

Posted in Stem Cells | Comments Off on STEM CELL UMBILICAL CORD BLOOD MARKET TRENDS, GROWTH, REGIONAL ANALYSIS, GROWTH REVENUE WITH TOP COMPANY’S AND FORECAST TO 2027 The Daily Chronicle -…

Page 903«..1020..902903904905..910920..»